Novartis Receives Positive CHMP Opinion for Tabrecta^® for Patients with METex14 Advanced Non-Small Cell Lung Cancer

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion and recommended granting marketing authorization of Tabrecta® as a monotherapy for the treatment of adults with advanced NSCLC.